138 related articles for article (PubMed ID: 16461424)
1. Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma.
Freeman BB; Iacono LC; Panetta JC; Gajjar A; Stewart CF
Neuro Oncol; 2006 Apr; 8(2):89-95. PubMed ID: 16461424
[TBL] [Abstract][Full Text] [Related]
2. A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma.
Zamboni WC; Gajjar AJ; Mandrell TD; Einhaus SL; Danks MK; Rogers WP; Heideman RL; Houghton PJ; Stewart CF
Clin Cancer Res; 1998 Oct; 4(10):2537-44. PubMed ID: 9796988
[TBL] [Abstract][Full Text] [Related]
3. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor.
Stewart CF; Iacono LC; Chintagumpala M; Kellie SJ; Ashley D; Zamboni WC; Kirstein MN; Fouladi M; Seele LG; Wallace D; Houghton PJ; Gajjar A
J Clin Oncol; 2004 Aug; 22(16):3357-65. PubMed ID: 15310781
[TBL] [Abstract][Full Text] [Related]
4. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.
Zamboni WC; Gajjar AJ; Heideman RL; Beijnen JH; Rosing H; Houghton PJ; Stewart CF
Clin Cancer Res; 1998 Mar; 4(3):783-9. PubMed ID: 9533548
[TBL] [Abstract][Full Text] [Related]
5. Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.
Shen J; Carcaboso AM; Hubbard KE; Tagen M; Wynn HG; Panetta JC; Waters CM; Elmeliegy MA; Stewart CF
Cancer Res; 2009 Jul; 69(14):5885-92. PubMed ID: 19567673
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
Akhtar S; Beckman RA; Mould DR; Doyle E; Fields SZ; Wright J
Cancer Chemother Pharmacol; 2000; 46(3):204-10. PubMed ID: 11021737
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.
Baker SD; Heideman RL; Crom WR; Kuttesch JF; Gajjar A; Stewart CF
Cancer Chemother Pharmacol; 1996; 37(3):195-202. PubMed ID: 8529278
[TBL] [Abstract][Full Text] [Related]
8. Comparative brain tissue distribution of camptothecin and topotecan in the rat.
El-Gizawy SA; Hedaya MA
Cancer Chemother Pharmacol; 1999; 43(5):364-70. PubMed ID: 10100590
[TBL] [Abstract][Full Text] [Related]
9. No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.
Zackrisson AL; Malmström H; Peterson C
Eur J Clin Pharmacol; 2002 May; 58(2):103-8. PubMed ID: 12012141
[TBL] [Abstract][Full Text] [Related]
10. The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid.
Zamboni WC; Lüftner DI; Egorin MJ; Schweigert M; Sezer O; Richter T; Natale JJ; Possinger K
Ann Oncol; 2001 Jan; 12(1):119-22. PubMed ID: 11249038
[TBL] [Abstract][Full Text] [Related]
11. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach.
Santana VM; Furman WL; Billups CA; Hoffer F; Davidoff AM; Houghton PJ; Stewart CF
J Clin Oncol; 2005 Jun; 23(18):4039-47. PubMed ID: 15961757
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors.
Santana VM; Zamboni WC; Kirstein MN; Tan M; Liu T; Gajjar A; Houghton PJ; Stewart CF
Clin Cancer Res; 2003 Feb; 9(2):633-40. PubMed ID: 12576429
[TBL] [Abstract][Full Text] [Related]
13. High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma.
Chen J; Balthasar JP
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Feb; 816(1-2):183-92. PubMed ID: 15664349
[TBL] [Abstract][Full Text] [Related]
14. Determining success rates of the current pharmacokinetically guided dosing approach of topotecan in pediatric oncology patients.
Mitchell AB; Vasilyeva A; Gajjar A; Santana VM; Stewart CF
Pediatr Blood Cancer; 2019 Apr; 66(4):e27578. PubMed ID: 30548417
[TBL] [Abstract][Full Text] [Related]
15. Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines.
Zamboni WC; Houghton PJ; Hulstein JL; Kirstein M; Walsh J; Cheshire PJ; Hanna SK; Danks MK; Stewart CF
Cancer Chemother Pharmacol; 1999; 43(4):269-76. PubMed ID: 10071976
[TBL] [Abstract][Full Text] [Related]
16. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
17. A modified surgical procedure for microdialysis probe implantation in the lateral ventricle of a FVB mouse.
Shen J; Fraga C; Calabrese C; McCarville MB; Schaiquevich P; Stewart CF
J Pharm Sci; 2008 Nov; 97(11):5013-23. PubMed ID: 18240294
[TBL] [Abstract][Full Text] [Related]
18. Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma.
Panetta JC; Schaiquevich P; Santana VM; Stewart CF
Clin Cancer Res; 2008 Jan; 14(1):318-25. PubMed ID: 18172284
[TBL] [Abstract][Full Text] [Related]
19. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors.
Zamboni WC; Bowman LC; Tan M; Santana VM; Houghton PJ; Meyer WH; Pratt CB; Heideman RL; Gajjar AJ; Pappo AS; Stewart CF
Cancer Chemother Pharmacol; 1999; 43(6):454-60. PubMed ID: 10321504
[TBL] [Abstract][Full Text] [Related]
20. Limited sampling model for area under the concentration time curve of total topotecan.
Minami H; Beijnen JH; Verweij J; Ratain MJ
Clin Cancer Res; 1996 Jan; 2(1):43-6. PubMed ID: 9816088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
